Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

Gunasekaran P, Inban P, Agrawal A, Thai A, Aravazhi PS, Tariq H, Prajjwal P, John J

Disease-a-month : DM15 Apr 2026

PMID41991422DOI10.1016/j.disamonth.2026.102113PepBankPUB-41991422

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study33

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In people with obesity, the systematic review reported 14.9% to 15.2% weight-loss magnitudes with semaglutide 2.4 mg weekly.
In plain wordsIn people with obesity, the review reported 14.9% to 15.2% weight loss with semaglutide 2.4 mg weekly.
Peptide
Semaglutide
Outcome
DecreaseWeight loss
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg/wk.As given in this study (human).
Measurements
weight loss
14.9 to 15.2%
semaglutide 2.4 mg/wk.
Source sentences
Summary
Weight loss was dose-dependent: semaglutide 2.4 mg/wk. -14.9% to -15.2%, tirzepatide 15-18.5%, liraglutide -8.8-11%, dulaglutide -1.3-2.0%, and dual GIP/GLP-1 therapy up to 21.5%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
Report a problemFND-4199142201
02HumanSystematic reviewEfficacy outcome
In people with obesity, the systematic review reported 15% to 18.5% weight-loss magnitudes with tirzepatide.
In plain wordsIn people with obesity, the review reported 15% to 18.5% weight loss with tirzepatide.
Peptide
Tirzepatide
Outcome
DecreaseWeight loss
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
weight loss
15 to 18.5%
tirzepatide
Source sentences
Summary
Weight loss was dose-dependent: semaglutide 2.4 mg/wk. -14.9% to -15.2%, tirzepatide 15-18.5%, liraglutide -8.8-11%, dulaglutide -1.3-2.0%, and dual GIP/GLP-1 therapy up to 21.5%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
Report a problemFND-4199142202
03HumanSystematic reviewEfficacy outcome
In people with obesity, the systematic review reported 8.8% to 11% weight-loss magnitudes with liraglutide.
In plain wordsIn people with obesity, the review reported 8.8% to 11% weight loss with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseWeight loss
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
weight loss
8.8 to 11%
liraglutide
Source sentences
Summary
Weight loss was dose-dependent: semaglutide 2.4 mg/wk. -14.9% to -15.2%, tirzepatide 15-18.5%, liraglutide -8.8-11%, dulaglutide -1.3-2.0%, and dual GIP/GLP-1 therapy up to 21.5%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
Report a problemFND-4199142203

Studies that did not test the peptide alone30

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with obesity, pooled GLP-1-based and related anti-obesity therapies had HbA1c reductions up to -1.78%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies reduced HbA1c by up to 1.78%.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Maximum reported HbA1c change
−1.78%
pooled GLP-1-based and related therapies; source says reductions up to -1.78%
Source sentences
Summary
Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142204
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with obesity, pooled GLP-1-based and related anti-obesity therapies had HbA1c reductions up to -1.78%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies reduced HbA1c by up to 1.78%.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Maximum reported HbA1c change
−1.78%
pooled GLP-1-based and related therapies; source says reductions up to -1.78%
Source sentences
Summary
Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142205
06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In people with obesity, pooled GLP-1-based and related anti-obesity therapies had HbA1c reductions up to -1.78%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies reduced HbA1c by up to 1.78%.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Maximum reported HbA1c change
−1.78%
pooled GLP-1-based and related therapies; source says reductions up to -1.78%
Source sentences
Summary
Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142206
07HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with obesity, pooled GLP-1-based and related therapies had reported nausea frequencies of 14.7% to 62%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies had nausea frequencies of 14.7% to 62%.
Peptide
Semaglutide
Outcome
Not applicableNausea
Study
n: not reported in source
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
nausea
14.7 to 62%
GLP-1-based and related therapies
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142207
08HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with obesity, pooled GLP-1-based and related therapies had reported nausea frequencies of 14.7% to 62%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies had nausea frequencies of 14.7% to 62%.
Peptide
Liraglutide
Outcome
Not applicableNausea
Study
n: not reported in source
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
nausea
14.7 to 62%
GLP-1-based and related therapies
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142208
09HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In people with obesity, pooled GLP-1-based and related therapies had reported nausea frequencies of 14.7% to 62%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies had nausea frequencies of 14.7% to 62%.
Peptide
Tirzepatide
Outcome
Not applicableNausea
Study
n: not reported in source
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
nausea
14.7 to 62%
GLP-1-based and related therapies
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142209
10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with obesity, pooled GLP-1-based and related therapies had reported vomiting frequencies of 3% to 30.3%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies had vomiting frequencies of 3% to 30.3%.
Peptide
Semaglutide
Outcome
Not applicableVomiting
Study
n: not reported in source
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
vomiting
3 to 30.3%
GLP-1-based and related therapies
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142210
11HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with obesity, pooled GLP-1-based and related therapies had reported vomiting frequencies of 3% to 30.3%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies had vomiting frequencies of 3% to 30.3%.
Peptide
Liraglutide
Outcome
Not applicableVomiting
Study
n: not reported in source
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
vomiting
3 to 30.3%
GLP-1-based and related therapies
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142211
12HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In people with obesity, pooled GLP-1-based and related therapies had reported vomiting frequencies of 3% to 30.3%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies had vomiting frequencies of 3% to 30.3%.
Peptide
Tirzepatide
Outcome
Not applicableVomiting
Study
n: not reported in source
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
vomiting
3 to 30.3%
GLP-1-based and related therapies
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142212
13HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with obesity, pooled GLP-1-based and related therapies had reported diarrhoea frequencies of 5% to 34.9%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies had diarrhoea frequencies of 5% to 34.9%.
Peptide
Semaglutide
Outcome
Not applicableDiarrhoea
Study
n: not reported in source
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
diarrhoea
5 to 34.9%
GLP-1-based and related therapies
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142213
14HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with obesity, pooled GLP-1-based and related therapies had reported diarrhoea frequencies of 5% to 34.9%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies had diarrhoea frequencies of 5% to 34.9%.
Peptide
Liraglutide
Outcome
Not applicableDiarrhoea
Study
n: not reported in source
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
diarrhoea
5 to 34.9%
GLP-1-based and related therapies
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142214
15HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In people with obesity, pooled GLP-1-based and related therapies had reported diarrhoea frequencies of 5% to 34.9%.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies had diarrhoea frequencies of 5% to 34.9%.
Peptide
Tirzepatide
Outcome
Not applicableDiarrhoea
Study
n: not reported in source
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
diarrhoea
5 to 34.9%
GLP-1-based and related therapies
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142215
16HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with obesity, pooled GLP-1-based and related therapies had reported SBP reductions of -5.28 to -7.8 mmHg.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies reduced systolic blood pressure by 5.28 to 7.8 mmHg.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure reduction
Study
n: not reported in source
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Measurements
Systolic blood pressure reduction magnitude
5.28 to 7.8 mmHg
pooled therapies; source reports signed reductions -5.28 to -7.8 mmHg
Source sentences
Summary
Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142219
17HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with obesity, pooled GLP-1-based and related therapies had reported SBP reductions of -5.28 to -7.8 mmHg.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies reduced systolic blood pressure by 5.28 to 7.8 mmHg.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure reduction
Study
n: not reported in source
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Measurements
Systolic blood pressure reduction magnitude
5.28 to 7.8 mmHg
pooled therapies; source reports signed reductions -5.28 to -7.8 mmHg
Source sentences
Summary
Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142220
18HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In people with obesity, pooled GLP-1-based and related therapies had reported SBP reductions of -5.28 to -7.8 mmHg.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies reduced systolic blood pressure by 5.28 to 7.8 mmHg.
Peptide
Tirzepatide
Outcome
DecreaseSystolic blood pressure reduction
Study
n: not reported in source
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Measurements
Systolic blood pressure reduction magnitude
5.28 to 7.8 mmHg
pooled therapies; source reports signed reductions -5.28 to -7.8 mmHg
Source sentences
Summary
Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142221
19HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with obesity, pooled GLP-1-based and related therapies had LDL-C decreases up to -11 mg/dL.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies lowered LDL cholesterol by up to 11 mg/dL.
Peptide
Semaglutide
Outcome
DecreaseLDL cholesterol decrease
Study
n: not reported in source
Analysis
Primary
Outcome group
Lipids · Cardiovascular
Measurements
Maximum reported LDL-C change
−11 mg/dL
pooled therapies; source says decreases up to -11 mg/dL
Source sentences
Summary
Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142222
20HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with obesity, pooled GLP-1-based and related therapies had LDL-C decreases up to -11 mg/dL.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies lowered LDL cholesterol by up to 11 mg/dL.
Peptide
Liraglutide
Outcome
DecreaseLDL cholesterol decrease
Study
n: not reported in source
Analysis
Primary
Outcome group
Lipids · Cardiovascular
Measurements
Maximum reported LDL-C change
−11 mg/dL
pooled therapies; source says decreases up to -11 mg/dL
Source sentences
Summary
Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142223
21HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In people with obesity, pooled GLP-1-based and related therapies had LDL-C decreases up to -11 mg/dL.
In plain wordsIn people with obesity, pooled GLP-1-based and related therapies lowered LDL cholesterol by up to 11 mg/dL.
Peptide
Tirzepatide
Outcome
DecreaseLDL cholesterol decrease
Study
n: not reported in source
Analysis
Primary
Outcome group
Lipids · Cardiovascular
Measurements
Maximum reported LDL-C change
−11 mg/dL
pooled therapies; source says decreases up to -11 mg/dL
Source sentences
Summary
Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142224
22HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with obesity, serious adverse events were reported as rare across pooled GLP-1-based and related therapies.
In plain wordsIn people with obesity, serious adverse events were reported as rare across pooled GLP-1-based and related therapies.
Peptide
Semaglutide
Outcome
Not applicableSerious adverse events
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Whole body
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142225
23HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with obesity, serious adverse events were reported as rare across pooled GLP-1-based and related therapies.
In plain wordsIn people with obesity, serious adverse events were reported as rare across pooled GLP-1-based and related therapies.
Peptide
Liraglutide
Outcome
Not applicableSerious adverse events
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Whole body
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142226
24HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In people with obesity, serious adverse events were reported as rare across pooled GLP-1-based and related therapies.
In plain wordsIn people with obesity, serious adverse events were reported as rare across pooled GLP-1-based and related therapies.
Peptide
Tirzepatide
Outcome
Not applicableSerious adverse events
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Whole body
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142227
25HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with obesity, pancreatitis was reported as rare across pooled GLP-1-based and related therapies.
In plain wordsIn people with obesity, pancreatitis was reported as rare across pooled GLP-1-based and related therapies.
Peptide
Semaglutide
Outcome
Not applicablePancreatitis
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142228
26HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with obesity, pancreatitis was reported as rare across pooled GLP-1-based and related therapies.
In plain wordsIn people with obesity, pancreatitis was reported as rare across pooled GLP-1-based and related therapies.
Peptide
Liraglutide
Outcome
Not applicablePancreatitis
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142229
27HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In people with obesity, pancreatitis was reported as rare across pooled GLP-1-based and related therapies.
In plain wordsIn people with obesity, pancreatitis was reported as rare across pooled GLP-1-based and related therapies.
Peptide
Tirzepatide
Outcome
Not applicablePancreatitis
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142230
28HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with obesity, gallbladder complications were reported as rare across pooled GLP-1-based and related therapies.
In plain wordsIn people with obesity, gallbladder complications were reported as rare across pooled GLP-1-based and related therapies.
Peptide
Semaglutide
Outcome
Not applicableGallbladder complications
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142231
29HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with obesity, gallbladder complications were reported as rare across pooled GLP-1-based and related therapies.
In plain wordsIn people with obesity, gallbladder complications were reported as rare across pooled GLP-1-based and related therapies.
Peptide
Liraglutide
Outcome
Not applicableGallbladder complications
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142232
30HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In people with obesity, gallbladder complications were reported as rare across pooled GLP-1-based and related therapies.
In plain wordsIn people with obesity, gallbladder complications were reported as rare across pooled GLP-1-based and related therapies.
Peptide
Tirzepatide
Outcome
Not applicableGallbladder complications
Study
n: not reported in source
Analysis
Primary
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
5 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
Summary · context
Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometabolic efficacy and safety using weight loss, glycemic control, cardiometabolic, gastro-intestinal tolerability, and serious adverse events as the primary variables.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142233
31HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with obesity, treatment discontinuation across pooled GLP-1-based and related therapies was generally below 15%.
In plain wordsIn people with obesity, treatment discontinuation across pooled GLP-1-based and related therapies was generally below 15%.
Peptide
Semaglutide
Outcome
Not applicableTreatment discontinuation
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Treatment discontinuation
< 15%
pooled therapies; generally below 15%, not a universal upper bound
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
4 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4199142216
32HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with obesity, treatment discontinuation across pooled GLP-1-based and related therapies was generally below 15%.
In plain wordsIn people with obesity, treatment discontinuation across pooled GLP-1-based and related therapies was generally below 15%.
Peptide
Liraglutide
Outcome
Not applicableTreatment discontinuation
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Treatment discontinuation
< 15%
pooled therapies; generally below 15%, not a universal upper bound
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
4 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4199142217
33HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In people with obesity, treatment discontinuation across pooled GLP-1-based and related therapies was generally below 15%.
In plain wordsIn people with obesity, treatment discontinuation across pooled GLP-1-based and related therapies was generally below 15%.
Peptide
Tirzepatide
Outcome
Not applicableTreatment discontinuation
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Treatment discontinuation
< 15%
pooled therapies; generally below 15%, not a universal upper bound
Source sentences
Summary
Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%.
4 context sentences(design, population, supporting numbers)
Summary · context
The systematic review, according to the PRISMA 2020 guidelines, analyzed the GLP-1-based anti-obesity pharmacotherapies.
Summary · context
Five databases were utilized to extract information from research studies related to the demographic and procedural framework, weight loss, cardiometabolic efficacy, and safety.
Summary · context
A total of 15 studies evaluated GLP-1-based and related anti-obesity therapies, including semaglutide, liraglutide, tirzepatide, dulaglutide, and dual GIP/GLP-1 receptor agonists.
Summary · context
Participants were predominantly female (up to 79.3%), with mean age 22.4-59.8 years, BMI 29.3-43.0 kg/m², and common comorbidities including hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, metabolic syndrome, OSA, MASLD, insulin resistance, and PCOS.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4199142218

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.